Valneva SE Reports Positive Travel Vaccine Results

Valneva SE today reported its consolidated financial results for the first half of the year, which ended June 30, 2024. On August 13, 2024, Valneva reported total revenues of €70.8 million, Net Profit of €34.0 million, and Cash position of €131.4 million.

Valneva’s commercial portfolio consists of three travel vaccines: IXIARO®/JESPECT®, DUKORAL®, and the recently launched IXCHIQ®, the first monovalent, single-dose, live-attenuated chikungunya vaccine approved by the U.S. Food and Drug Administration.

The Company recently confirmed that IXCHIQ's two-year antibody persistence data were published in the Lancet Infectious Diseases and reported positive six-month data for the Phase 3 adolescent study of IXCHIQ; it expects to submit label extensions for 12 to 17 years in the U.S., Europe, and Canada in the second half of 2024.

In a press release, Peter Bühler, Valneva’s Chief Financial Officer, commented, “Our first half sales performance is in line with our expectations."

"We aim to further capitalize on the travel industry recovery as we focus on ramping up sales for IXCHIQ® to support our commercial growth while continuing to execute on our key R&D and regulatory milestones."

The Company also distributes certain third-party products in countries where it operates its own marketing and sales infrastructure.

For example, the Company has an exclusive worldwide license for the S4V Shigella vaccine candidate, adding an attractive Phase 2 clinical asset to Valneva’s R&D pipeline without impacting full-year or mid-term financial guidance.

The half-year financial report, including the condensed consolidated interim financial report and the half-year management report, is available on the Company’s website (Financial Reports—Valneva). 

On August 13, 2024, Valneva CEO Thomas Lingelbach spoke on YouTube about the Company’s half-year results and plans for the rest of 2024.